Literature DB >> 32654104

Donor egg is the best second choice for many infertile couples: real progress in overcoming age-related fertility is not here yet.

Reeva Makhijani1, Daniel R Grow2.   

Abstract

Entities:  

Keywords:  Genetic engineering; IVF adjuvants; IVF stimulation; Oocyte donation

Mesh：

Year:  2020        PMID： 32654104      PMCID： PMC7376777          DOI： 10.1007/s10815-020-01880-w

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN： 1058-0468            Impact factor:   3.412


× No keyword cloud information.
  15 in total

1.  Error-prone mammalian female meiosis from silencing the spindle assembly checkpoint without normal interkinetochore tension.

Authors:  Agnieszka Kolano; Stéphane Brunet; Alain D Silk; Don W Cleveland; Marie-Hélène Verlhac
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-02       Impact factor: 11.205

2.  Ooplasmic transfer in mature human oocytes.

Authors:  J Cohen; R Scott; M Alikani; T Schimmel; S Munné; J Levron; L Wu; C Brenner; C Warner; S Willadsen
Journal:  Mol Hum Reprod       Date:  1998-03       Impact factor: 4.025

Review 3.  The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening.

Authors:  Jason M Franasiak; Eric J Forman; Kathleen H Hong; Marie D Werner; Kathleen M Upham; Nathan R Treff; Richard T Scott
Journal:  Fertil Steril       Date:  2013-12-17       Impact factor: 7.329

Review 4.  Insights from clinical experience in treating IVF poor responders.

Authors:  Kelly J Gonda; Alice D Domar; Norbert Gleicher; Richard P Marrs
Journal:  Reprod Biomed Online       Date:  2017-10-24       Impact factor: 3.828

5.  Surrogate mothers 10 years on: a longitudinal study of psychological well-being and relationships with the parents and child.

Authors:  V Jadva; S Imrie; S Golombok
Journal:  Hum Reprod       Date:  2014-12-19       Impact factor: 6.918

6.  Growth hormone co-treatment in IVF/ICSI cycles in poor responders.

Authors:  Ksenia Ob'edkova; Igor Kogan; Inna Krikheli; Lyailya Dzhemlikhanova; Valeria Muller; Irina Mekina; Elena Lesik; Evgenia Komarova; Maria Mazilina; Dariko Niauri; Alexandr Gzgzyan; Edward Aylamazyan
Journal:  Gynecol Endocrinol       Date:  2017       Impact factor: 2.260

7.  Preimplantation genetic diagnosis for aneuploidy testing in women older than 44 years: a multicenter experience.

Authors:  Filippo Maria Ubaldi; Danilo Cimadomo; Antonio Capalbo; Alberto Vaiarelli; Laura Buffo; Elisabetta Trabucco; Susanna Ferrero; Elena Albani; Laura Rienzi; Paolo E Levi Setti
Journal:  Fertil Steril       Date:  2017-04-19       Impact factor: 7.329

Review 8.  Telomeres, Reproductive Aging, and Genomic Instability During Early Development.

Authors:  David L Keefe
Journal:  Reprod Sci       Date:  2016-12       Impact factor: 3.060

9.  Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women.

Authors:  Yvonne A R White; Dori C Woods; Yasushi Takai; Osamu Ishihara; Hiroyuki Seki; Jonathan L Tilly
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

10.  CRISPR/Cas9-mediated targeted chromosome elimination.

Authors:  Erwei Zuo; Xiaona Huo; Xuan Yao; Xinde Hu; Yidi Sun; Jianhang Yin; Bingbing He; Xing Wang; Linyu Shi; Jie Ping; Yu Wei; Wenqin Ying; Wei Wei; Wenjia Liu; Cheng Tang; Yixue Li; Jiazhi Hu; Hui Yang
Journal:  Genome Biol       Date:  2017-11-24       Impact factor: 13.583
View more
  2 in total

1.  Is It Possible to Expand Oocyte Donors by Decreasing Number of Oocytes for Own Use? Insights From a Large Single-Center Study.

Authors:  Zhiqin Bu; Jiaxin Zhang; Yile Zhang; Yingpu Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-11       Impact factor: 5.555

Review 2.  Prospects of Germline Nuclear Transfer in Women With Diminished Ovarian Reserve.

Authors:  Antonia Christodoulaki; Annekatrien Boel; Maoxing Tang; Chloë De Roo; Dominic Stoop; Björn Heindryckx
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-22       Impact factor: 5.555
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.